Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for
PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab)
Results Demonstrate Equivalence in Objective Response Rate in Patients with HER2-positive
Metastatic Breast Cancer
Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of
PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint. PF-05280014 is being developed by Pfizer as a potential
biosimilar to Herceptin.
The trial demonstrated equivalence in the primary endpoint of objective response rate (ORR) of PF-05280014 versus Herceptin,
taken in combination with paclitaxel, in first line patients with HER2-positive metastatic breast cancer. ORR is defined as the
proportion of patients with tumor size reduction of a predefined amount and for a minimum period of time2.
“As the leading global biosimilars company, we are committed to advancing our robust pipeline of biosimilar therapies in hopes
of expanding access to high-quality treatment options for patients living with serious, life-threatening conditions such as
cancer,” said Sumant Ramachandra, MD, PhD, MBA, Head of Research and Development, Pfizer Essential Health. “Favorable comparative
clinical data between proposed biosimilars and their respective reference product contribute to physician and patient understanding
of and confidence in the value and importance of biosimilars. We are encouraged by these data and look forward to sharing the
complete results with health authorities and the oncology community once available.”
A separate comparative, randomized, double-blind clinical trial [REFLECTIONS B3271004] in early breast cancer patients [N=226]
also met its primary endpoint of steady-state Ctrough concentrations (PK) in patients treated with PF-05280014 and
Herceptin.
About the REFLECTIONS B3271002 Study
REFLECTIONS B3271002 is a comparative, randomized, double blind, clinical trial[N=690] evaluating the efficacy, safety,
pharmacokinetics (PK) and immunogenicity of PF-05280014 (a potential biosimilar to Herceptin® [trastuzumab]) in combination with
paclitaxel versus Herceptin in combination with paclitaxel in first line patients with HER2-positive metastatic breast cancer. The
primary endpoint is objective response rate (ORR) by Week 25 of study treatment. ORR is defined as the proportion of patients with
tumor size reduction of a predefined amount and for a minimum period of time2.
More information about the PF-05280014 REFLECTIONS B3271002 and B3271004 studies can be found at www.clinicaltrials.gov.
About PF-05280014
PF-05280014 is a monoclonal antibody (mAb) that is in development as a potential biosimilar for all currently approved
indications of Herceptin® (trastuzumab).
Herceptin is currently approved in the U.S., EU and other markets for HER2-positive breast cancer and gastric cancer.
PF-05280014 is an investigational compound and has not received regulatory approval in any country. Biosimilarity has not yet
been established by regulatory authorities and is not yet claimed.
About Pfizer: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference
for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is as of November 30, 2016. Pfizer assumes no obligation to
update forward-looking statements contained in this release as the result of new information or future events or
developments.
This release contains forward-looking information about PF-05280014, including its potential benefits, that involves
substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such
statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including
the ability to meet anticipated trial commencement and completion dates and regulatory submission dates, as well as the possibility
of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data;
whether and when any applications for PF-05280014 may be filed with regulatory authorities in any jurisdictions; whether and when
regulatory authorities in any such jurisdictions may approve any such applications for PF-05280014, which will depend on the
assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety
information submitted; intellectual property and/or litigation implications; decisions by regulatory authorities regarding labeling
and other matters that could affect the availability or commercial potential of PF-05280014; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year
ended December 31, 2015, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors
That May Affect Future Results", as well as in its subsequent reports on Form 10-Q and Form 8-K, all of which are filed with the
U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
1 Herceptin® is a registered US trademark of Genentech, Inc.
2 United States Food and Drug Administration. Guidance for Industry: Clinical Trial Endpoints for the Approval of
Cancer Drugs and Biologics. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071590.pdf. Accessed October 27, 2016.
Pfizer Inc.
Media
Rachel Hooper, 916-708-1868
Rachel.Hooper@pfizer.com
or
Investors
Ryan Crowe, 212-733-8160
Ryan.Crowe@pfizer.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161130005258/en/